

IAEA/ESNM Webinar Series on basic NM

Basic Principles of Radionuclide Therapy and Common Clinical Applications

Suggested Reading

1. Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögren-Gleisner K. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ^{177}Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. *J Nucl Med*. 2016 Jan;57(1):151-62.
2. Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, Lassmann M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. *Eur J Nucl Med Mol Imaging*. 2013 Jul;40(7):1126-34.
3. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2013 May;40(5):800-16.
4. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, Brans B, Lambert B, Konijnenberg M, Borson-Chazot F, Tennvall J, Luster M; Therapy, Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. *Eur J Nucl Med Mol Imaging*. 2011 Jul;38(7):1393-406.
5. Lassmann M, Chiesa C, Flux G, Bardiès M; EANM Dosimetry Committee. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. *Eur J Nucl Med Mol Imaging*. 2011 Jan;38(1):192-200.
6. Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. *Eur J Nucl Med Mol Imaging*. 2010 Nov;37(11):2218-28.
7. Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. *Front Med (Lausanne)*. 2015 Mar 17;2:12.
8. Navarro-Teulon I, Lozza C, Pèlegri A, Vivès E, Pouget JP. General overview of radioimmunotherapy of solid tumors. *Immunotherapy*. 2013 May;5(5):467-87.
9. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging*. 2015 Jan;42(1):5-19.
10. Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack HJ, Nagarajah J, Ezziddin S. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (^{177}Lu) -octreotate. *Eur J Nucl Med Mol Imaging*. 2014 Mar;41(3):505-10.
11. Clement SC, Peeters RP, Ronckers CM, Links TP, van den Heuvel-Eibrink MM, Nieveen van Dijkum EJ, van Rijn RR, van der Pal HJ, Neggers SJ, Kremer LC, van Eck-Smit BL, van Santen HM. Intermediate and long-term adverse effects of radioiodine therapy

- for differentiated thyroid carcinoma--a systematic review. *Cancer Treat Rev.* 2015 Dec;41(10):925-34.
12. Ko KY, Kao CH, Lin CL, Huang WS, Yen RF. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. *Eur J Nucl Med Mol Imaging.* 2015 Jul;42(8):1172-8.
 13. Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. *Eur Urol.* 2015 Sep 18. pii: S0302-2838(15)00862-3.
 14. Maffioli L, Florimonte L, Costa DC, Correia Castanheira J, Grana C, Luster M, Bodei L, Chinol M. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. *Q J Nucl Med Mol Imaging.* 2015 Dec;59(4):420-38.
 15. Kumar C, Shetake N, Desai S, Kumar A, Samuel G, Pandey BN. Relevance of radiobiological concepts in radionuclide therapy of cancer. *Int J Radiat Biol.* 2016 Apr;92(4):173-86.
 16. Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, de Jong M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. *Clin Transl Imaging.* 2014;2:55-66.
 17. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD Continuing Education: Bystander and Low-Dose-Rate Effects: Are These Relevant to Radionuclide Therapy? *J Nucl Med* 2007; 48: 1683–1691.